Overview
- The blood test analyzes transfer RNA fragments (tRFs) and mitochondrial RNA levels to detect early molecular changes linked to Parkinson’s disease.
- Using PCR technology, the test amplifies genetic markers for accurate detection, leveraging infrastructure from the COVID-19 era.
- The test demonstrated 86% accuracy in distinguishing Parkinson’s patients, including those with subtle early symptoms, from healthy individuals.
- Early diagnosis could enable timely therapeutic interventions to protect dopamine-producing brain cells and potentially slow disease progression.
- Led by Professor Hermona Soreq, the research team has filed provisional patents and is preparing for large-scale diagnostic trials to support clinical adoption.